JP2007532594A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007532594A5 JP2007532594A5 JP2007507707A JP2007507707A JP2007532594A5 JP 2007532594 A5 JP2007532594 A5 JP 2007532594A5 JP 2007507707 A JP2007507707 A JP 2007507707A JP 2007507707 A JP2007507707 A JP 2007507707A JP 2007532594 A5 JP2007532594 A5 JP 2007532594A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- phenyl
- groups
- atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 Alkyne compounds Chemical class 0.000 claims 43
- 125000004432 carbon atoms Chemical group C* 0.000 claims 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 15
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 12
- PIGFYZPCRLYGLF-UHFFFAOYSA-N aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims 11
- 229910052740 iodine Inorganic materials 0.000 claims 11
- 125000004076 pyridyl group Chemical group 0.000 claims 10
- 229910052801 chlorine Inorganic materials 0.000 claims 9
- 239000000460 chlorine Substances 0.000 claims 9
- 125000004122 cyclic group Chemical group 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000011780 sodium chloride Substances 0.000 claims 9
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 8
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 8
- 239000011630 iodine Substances 0.000 claims 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 8
- 239000000126 substance Substances 0.000 claims 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 7
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 229910052794 bromium Inorganic materials 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- LSXDOTMGLUJQCM-UHFFFAOYSA-M Copper(I) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000002837 carbocyclic group Chemical group 0.000 claims 4
- 239000003054 catalyst Substances 0.000 claims 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 239000012467 final product Substances 0.000 claims 4
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 4
- 229910052763 palladium Inorganic materials 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 125000005842 heteroatoms Chemical group 0.000 claims 3
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 230000003042 antagnostic Effects 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 150000004820 halides Chemical class 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 125000004430 oxygen atoms Chemical group O* 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000004434 sulfur atoms Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 1
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 claims 1
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 claims 1
- 125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 claims 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 claims 1
- 206010002855 Anxiety Diseases 0.000 claims 1
- 206010057666 Anxiety disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003246 Arthritis Diseases 0.000 claims 1
- 125000003830 C1- C4 alkylcarbonylamino group Chemical group 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010012378 Depression Diseases 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 206010062060 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108010047068 Melanin-concentrating hormone receptors Proteins 0.000 claims 1
- 208000008466 Metabolic Disease Diseases 0.000 claims 1
- 150000001345 alkine derivatives Chemical class 0.000 claims 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 1
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 230000000378 dietary Effects 0.000 claims 1
- 235000021061 dietary behavior Nutrition 0.000 claims 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 235000006694 eating habits Nutrition 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 150000002366 halogen compounds Chemical class 0.000 claims 1
- 230000002140 halogenating Effects 0.000 claims 1
- 150000002466 imines Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 102000006953 melanin-concentrating hormone receptor activity proteins Human genes 0.000 claims 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 1
- 229940113083 morpholine Drugs 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
Claims (19)
- äžè¬åŒïŒ©ã®ã¢ã«ãã³ååç©ããããã®äºå€ç°æ§äœããžã¢ã¹ãã¬ãªããŒãé¡åäœãæ··åç©åã¯ãããã®å¡©ã
R1ãR2ã¯äºãã«ç¬ç«ã«ïŒšãC1-8-ã¢ã«ãã«ãC3-7-ã·ã¯ãã¢ã«ãã«åã¯ãã§ãã«åºãããã¯ããªãžãã«åºïŒå¿ èŠã«ããåãåã¯ç°ãªãåºR20ã«ããäžçœ®æãããã¯å€çœ®æãããŠããŠãããããã€ïŒåã¯ãããã«ãã眮æãããŠããŠãããïŒãè¡šãããã®ã¢ã«ãã«åºåã¯ã·ã¯ãã¢ã«ãã«åºã¯åãåã¯ç°ãªãåºR11ã«ããäžçœ®æåã¯å€çœ®æãããŠããŠãããããã€ïŒå¡ãïŒå¡åã¯ïŒå¡ã·ã¯ãã¢ã«ãã«åºã®ïŒäœåã¯ïŒäœã®-CH2-åºã¯-O-ã-Såã¯-NR13-ã«ãã眮æãããŠããŠããããåã¯
R1åã³R2ã¯C3-8-ã¢ã«ãã¬ã³ããªããžã圢æããR1R2Nåºã®ïŒ®ååã«é£æ¥ããªã-CH2-åºã¯-CH=N-ã-CH=CH-ã-O-ã-S-ã-SO-ã-(SO2)-ã-CO-ã-C(=CH2)-åã¯-NR13-ã«ãã眮æãããŠããŠãããã
å ã«å®çŸ©ãããã¢ã«ãã¬ã³ããªããžäžã§ãïŒå以äžã®ïŒšååãåãåã¯ç°ãªãåºR14ã«ãã眮æãããŠããŠãããããã€
å ã«å®çŸ©ãããã¢ã«ãã¬ã³ããªããžã¯ã¢ã«ãã¬ã³ããªããžãšåºCyã®éã®çµåã
âåçµååã¯äºéçµåãä»ããŠã
âã¹ããç°åŒç°ç³»ã圢æããå ±éã®ïŒ£ååãä»ããŠã
âçž®åäºç°åŒç°ç³»ã圢æããïŒåã®å ±éã®é£æ¥ïŒ£åååã³ïŒåã¯ïŒ®ååãä»ããŠãåã¯
âããªããžãããç°ç³»ã圢æããïŒå以äžã®ïŒ£åååã³ïŒåã¯ïŒ®ååãä»ããŠ
ã€ãããããããªæ§åŒã§ïŒååã¯ïŒåã®åãåã¯ç°ãªãççŽ ç°åºåã¯è€çŽ ç°åºCyã«ãã眮æãããŠããŠãããã
ãã¯äºãã«ç¬ç«ã«åçµååã¯C1-2-ã¢ã«ãã¬ã³ããªããžãè¡šãã
äºã€ã®é£æ¥ïŒ£ååãä»å çãªC1-4-ã¢ã«ãã¬ã³ããªããžãšäžç·ã«çµåãããŠãããããã€
ïŒååã¯ïŒåã®ïŒ£ååãäºãã«ç¬ç«ã«ïŒååã¯ïŒåã®åãåã¯ç°ãªãC1-3-ã¢ã«ãã«åºã«ãã眮æãããŠããŠããããäºã€ã®ã¢ã«ãã«åºãäžç·ã«çµåãããŠççŽ ç°åŒç°ã圢æããŠãããããã€
ã¯éšååŒY1ãY9ã®å®çŸ©ããéžã°ãã
éšååŒY1ãY9äžã§ãïŒå以äžã®ïŒ£ååãäºãã«ç¬ç«ã«R20ã«ãã眮æãããŠããŠãããããã€
éšååŒY5åã³Y6äžã§ãNHåºã¯C1-4-ã¢ã«ãã«ã«ãã眮æãããŠããŠãããïŒ
ã¯ïŒäŸ¡ã®ç°åŒåºãã§ãã«ãããªãžãã«ãããªããžãã«ããã©ãžãã«ãããªããžãã«ããããã«ãããã©ããããããã«ãã€ã³ããªã«ããžãããã€ã³ããªã«ããããªãã«ããžããããããªãã«ãããã©ããããããªãã«ãã€ãœãããªãã«ããžãããã€ãœãããªãã«ãããã©ããã-ã€ãœãããªãã«ããã³ãŸã€ãããŸãªã«ããã³ãŸãªããµãŸãªã«ãããšãã«ããã©ãã«ããã³ãŸããšãã«åã¯ãã³ãŸãã©ãã«ã®äžããéžã°ããäžèšç°åŒåºã¯äžã€ä»¥äžã®Cååã®äœçœ®ã§åãåã¯ç°ãªãåºR20ã«ããäžçœ®æåã¯å€çœ®æãããŠããŠããããåã¯ãã§ãã«ç°ã®å Žåã«ã¯ãŸãæŽã«ãããã«ããäžçœ®æãããŠããŠãããããã€ïŒåã¯ïŒå以äžã®NHåºã¯R21ã«ãã眮æãããŠããŠãããã
ã¯ïŒ¹ãã«ã€ããŠç€ºãããæå³ã®äžã€ãæããåã¯
C1-6-ã¢ã«ãã«ãC1-6-ã¢ã«ã±ãã«ãC1-6-ã¢ã«ããã«ãC3-7-ã·ã¯ãã¢ã«ãã«ãC5-7-ã·ã¯ãã¢ã«ã±ãã«ãC3-7-ã·ã¯ãã¢ã«ãã«-C1-3-ã¢ã«ãã«ãC3-7-ã·ã¯ãã¢ã«ã±ãã«-C1-3-ã¢ã«ãã«ãC3-7-ã·ã¯ãã¢ã«ãã«-C1-3-ã¢ã«ã±ãã«åã¯C3-7-ã·ã¯ãã¢ã«ãã«-C1-3-ã¢ã«ããã«ãè¡šããïŒå以äžã®ïŒ£ååãäºãã«ç¬ç«ã«ããã²ã³ã«ããäžçœ®æåã¯å€çœ®æãããŠããŠãããããã€ïŒåã¯ããããã·ãããã¯ã·ã¢ãã«ããäžçœ®æãããŠããŠãããããã€ïŒåã¯ç°åŒåºãåãåã¯ç°ãªãåºR20ã«ããäžçœ®æåã¯å€çœ®æãããŠããŠãããã
Cyã¯äžèšã®æå³
â飜åïŒãïŒå¡ççŽ ç°åºã
âäžé£œåïŒãïŒå¡ççŽ ç°åºã
âãã§ãã«åºã
âãããååãšããŠïŒ®ãåã¯ïŒ³ååãæãã飜åïŒãïŒå¡åã¯äžé£œåïŒãïŒå¡è€çŽ ç°åºã
âãããååãšããŠïŒå以äžã®ïŒ®åååã¯ïŒåãããã¯ïŒåã®ïŒ®ååãšïŒåã®ïŒ¯åã¯ïŒ³ååãæãã飜ååã¯äžé£œåïŒãïŒå¡è€çŽ ç°åºã
âãåã³ïŒåã¯ïŒ³ããéžã°ããïŒå以äžã®åãåã¯ç°ãªããããååãæããè³éŠæè€çŽ ç°ïŒå¡åã¯ïŒå¡åº
ã®äžã€ããéžã°ããççŽ ç°åºåã¯è€çŽ ç°åºãè¡šãã
äžèšé£œåïŒå¡åã¯ïŒå¡åºã¯ãŸãã€ããããªããžã(C1-4-ã¢ã«ãã«)-ã€ããããªããžãã¡ãã¬ã³ããªããžã(C1-4-ã¢ã«ãã«)-ã¡ãã¬ã³ããªããžåã¯ãž-(C1-4-ã¢ã«ãã«)-ã¡ãã¬ã³ããªããžã§ããªããžãããç°ç³»ãšããŠååšããŠãããããã€
äžèšç°åŒåºã¯ïŒå以äžã®ïŒ£ååã®äœçœ®ã§åãåã¯ç°ãªãåºR20ã«ããäžçœ®æåã¯å€çœ®æãããŠããŠããããåã¯ãã§ãã«åºã®å Žåã«ã¯ãŸãæŽã«ãããã«ããäžçœ®æãããŠããŠãããããã€ïŒåã¯ïŒå以äžã®NHåºãR21ã«ãã眮æãããŠããŠãããã
R11ã¯ããã²ã³ãC1-6-ã¢ã«ãã«ãC2-6-ã¢ã«ã±ãã«ãC2-6-ã¢ã«ããã«ãR15-O-ãR15-O-CO-ãR15-CO-Oãã·ã¢ããR16R17NãR18R19N-CO-åã¯Cyãè¡šããäžèšåºäžã§ãïŒå以äžã®ïŒ£ååãäºãã«ç¬ç«ã«ããã²ã³ãOHãCNãCF3ãC1-3-ã¢ã«ãã«ãããããã·-C1-3-ã¢ã«ãã«ããéžã°ãã眮æåºã«ãã眮æãããŠããŠãããã
R13ã¯R17ã«ã€ããŠç€ºãããæå³ã®äžã€ãæãã
R14ã¯ããã²ã³ãã·ã¢ããC1-6-ã¢ã«ãã«ãC2-6-ã¢ã«ã±ãã«ãC2-6-ã¢ã«ããã«ãR15-O-ãR15-O-CO-ãR15-CO-ãR15-CO-O-ãR16R17NãR18R19N-CO-ãR15-O-C1-3-ã¢ã«ãã«ãR15-O-CO-C1-3-ã¢ã«ãã«ãR15-SO2-NHãR15-O-CO-NH-C1-3-ã¢ã«ãã«ãR15-SO2-NH-C1-3-ã¢ã«ãã«ãR15-CO-C1-3-ã¢ã«ãã«ãR15-CO-O-C1-3-ã¢ã«ãã«ãR16R17N-C1-3-ã¢ã«ãã«ãR18R19N-CO-C1-3-ã¢ã«ãã«åã¯Cy-C1-3-ã¢ã«ãã«ãè¡šãã
R15ã¯ïŒšãC1-4-ã¢ã«ãã«ãC3-7-ã·ã¯ãã¢ã«ãã«ãC3-7-ã·ã¯ãã¢ã«ãã«-C1-3-ã¢ã«ãã«ããã§ãã«ããã§ãã«-C1-3-ã¢ã«ãã«ãããªãžãã«åã¯ããªãžãã«-C1-3-ã¢ã«ãã«ãè¡šãã
R16ã¯ïŒšãC1-6-ã¢ã«ãã«ãC3-7-ã·ã¯ãã¢ã«ãã«ãC3-7-ã·ã¯ãã¢ã«ãã«-C1-3-ã¢ã«ãã«ãC4-7-ã·ã¯ãã¢ã«ã±ãã«ãC4-7-ã·ã¯ãã¢ã«ã±ãã«-C1-3-ã¢ã«ãã«ãÏ-ããããã·-C2-3-ã¢ã«ãã«ãÏ-(C1-4-ã¢ã«ã³ãã·)-C2-3-ã¢ã«ãã«ãã¢ãã-C2-6-ã¢ã«ãã«ãC1-4-ã¢ã«ãã«-ã¢ãã-C2-6-ã¢ã«ãã«ããž-(C1-4-ã¢ã«ãã«)-ã¢ãã-C2-6-ã¢ã«ãã«åã¯ã·ã¯ã-C3-6-ã¢ã«ãã¬ã³ã€ãã-C2-6-ã¢ã«ãã«ãè¡šãã
R17ã¯R16ã«ã€ããŠç€ºãããæå³ã®äžã€ãæããåã¯ãã§ãã«ããã§ãã«-C1-3-ã¢ã«ãã«ãããªãžãã«ãC1-4-ã¢ã«ãã«ã«ã«ããã«ãããããã·ã«ã«ããã«-C1-3-ã¢ã«ãã«ãC1-4-ã¢ã«ã³ãã·ã«ã«ããã«ãC1-4-ã¢ã«ã³ãã·ã«ã«ããã«-C1-3-ã¢ã«ãã«ãC1-4-ã¢ã«ãã«ã«ã«ããã«ã¢ãã-C2-3-ã¢ã«ãã«ãN-(C1-4-ã¢ã«ãã«ã«ã«ããã«)-N-(C1-4-ã¢ã«ãã«)-ã¢ãã-C2-3-ã¢ã«ãã«ãC1-4-ã¢ã«ãã«ã¹ã«ããã«ãC1-4-ã¢ã«ãã«ã¹ã«ããã«ã¢ãã-C2-3-ã¢ã«ãã«ãããã¯N-(C1-4-ã¢ã«ãã«ã¹ã«ããã«)-N-(C1-4-ã¢ã«ãã«)-ã¢ãã-C2-3-ã¢ã«ãã«ãè¡šãã
R18ãR19ã¯äºã«ç¬ç«ã«ïŒšåã¯C1-6-ã¢ã«ãã«ãè¡šãã
R20ã¯ããã²ã³ãããããã·ãã·ã¢ããC1-6-ã¢ã«ãã«ãC2-6-ã¢ã«ã±ãã«ãC2-6-ã¢ã«ããã«ãC3-7-ã·ã¯ãã¢ã«ãã«ãC3-7-ã·ã¯ãã¢ã«ãã«-C1-3-ã¢ã«ãã«ãããããã·-C1-3-ã¢ã«ãã«ãR22-C1-3-ã¢ã«ãã«ãè¡šããåã¯R22ã«ã€ããŠç€ºãããæå³ã®äžã€ãæãã
R21ã¯C1-4-ã¢ã«ãã«ãÏ-ããããã·-C2-6-ã¢ã«ãã«ãÏ-C1-4-ã¢ã«ã³ãã·-C2-6-ã¢ã«ãã«ãÏ-C1-4-ã¢ã«ãã«-ã¢ãã-C2-6-ã¢ã«ãã«ãÏ-ãž-(C1-4-ã¢ã«ãã«)-ã¢ãã-C2-6-ã¢ã«ãã«ãÏ-ã·ã¯ã-C3-6-ã¢ã«ãã¬ã³ã€ãã-C2-6-ã¢ã«ãã«ããã§ãã«ããã§ãã«-C1-3-ã¢ã«ãã«ãC1-4-ã¢ã«ãã«-ã«ã«ããã«ãC1-4-ã¢ã«ã³ãã·-ã«ã«ããã«ãC1-4-ã¢ã«ãã«ã¹ã«ããã«ãã¢ããã¹ã«ããã«ãC1-4-ã¢ã«ãã«ã¢ããã¹ã«ããã«ããž-C1-4-ã¢ã«ãã«ã¢ããã¹ã«ããã«åã¯ã·ã¯ã-C3-6-ã¢ã«ãã¬ã³ã€ãã-ã¹ã«ããã«ãè¡šãã
R22ã¯ããªãžãã«ããã§ãã«ããã§ãã«-C1-3-ã¢ã«ã³ãã·ãã·ã¯ã-C3-6-ã¢ã«ãã¬ã³ã€ãã-C2-4-ã¢ã«ã³ãã·ãOHC-ãHO-N=HC-ãC1-4-ã¢ã«ã³ãã·-N=HC-ãC1-4-ã¢ã«ã³ãã·ãC1-4-ã¢ã«ãã«ããªãã«ã«ããã·ãC1-4-ã¢ã«ãã«ã«ã«ããã«ãC1-4-ã¢ã«ã³ãã·ã«ã«ããã«ãã¢ããã«ã«ããã«ãC1-4-ã¢ã«ãã«ã¢ããã«ã«ããã«ããž-(C1-4-ã¢ã«ãã«)-ã¢ããã«ã«ããã«ãã·ã¯ã-C3-6-ã¢ã«ãã«-ã¢ãã-ã«ã«ããã«ãã·ã¯ã-C3-6-ã¢ã«ãã¬ã³ã€ãã-ã«ã«ããã«ããã§ãã«ã¢ããã«ã«ããã«ãã·ã¯ã-C3-6-ã¢ã«ãã¬ã³ã€ãã-C2-4-ã¢ã«ãã«-ã¢ããã«ã«ããã«ãC1-4-ã¢ã«ãã«-ã¹ã«ããã«ãC1-4-ã¢ã«ãã«-ã¹ã«ãã£ãã«ãC1-4-ã¢ã«ãã«-ã¹ã«ããã«ã¢ãããã¢ãããC1-4-ã¢ã«ãã«ã¢ããããž-(C1-4-ã¢ã«ãã«)-ã¢ãããC1-4-ã¢ã«ãã«-ã«ã«ããã«-ã¢ãããã·ã¯ã-C3-6-ã¢ã«ãã¬ã³ã€ããããã§ãã«-C1-3-ã¢ã«ãã«ã¢ãããN-(C1-4-ã¢ã«ãã«)-ãã§ãã«-C1-3-ã¢ã«ãã«ã¢ãããã¢ã»ãã«ã¢ãããããããªãã«ã¢ããããã§ãã«ã«ã«ããã«ããã§ãã«ã«ã«ããã«ã¢ããããã§ãã«ã«ã«ããã«ã¡ãã«ã¢ãããããããã·-C2-3-ã¢ã«ãã«ã¢ããã«ã«ããã«ã(4-ã¢ã«ããªãã«)ã«ã«ããã«ã(1-ãããªãžãã«)ã«ã«ããã«ã(1-ãããªãžãã«)ã«ã«ããã«ãïŒãããµããã-1-ã¢ãŒããã«ïŒã«ã«ããã«ã(4-ã¡ãã«-1-ããã©ãžãã«)ã«ã«ããã«ãã¡ãã¬ã³ãžãªãã·ãã¢ããã«ã«ããã«ã¢ããåã¯C1-4-ã¢ã«ãã«ã¢ããã«ã«ããã«ã¢ãããè¡šãã
äžèšåºãç¹ã«ïŒ·ããR13ãR22äžã§ã倫ã ã®å Žåã«ïŒå以äžã®ïŒ£ååãæŽã«ïŒŠã«ããäžçœ®æåã¯å€çœ®æãããŠããŠãããããã€ïŒåã¯å€«ã ã®å Žåã«ïŒååã¯ïŒåã®ïŒ£ååãäºã«ç¬ç«ã«æŽã«Clåã¯Brã«ããäžçœ®æãããŠããŠãããããã€ïŒåã¯å€«ã ã®å Žåã«ïŒå以äžã®ãã§ãã«ç°ãäºã«ç¬ç«ã«æŽã«åºïŒŠãClãBrããã·ã¢ããC1-4-ã¢ã«ãã«ãC1-4-ã¢ã«ã³ãã·ããžãã«ãªãã¡ãã«ãããªãã«ãªãã¡ãã«ãããããã·ãã¢ãããC1-3-ã¢ã«ãã«ã¢ããããž-(C1-3-ã¢ã«ãã«)-ã¢ãããã¢ã»ãã«ã¢ãããã¢ããã«ã«ããã«ããžãã«ãªãã¡ããã·ãããªãã«ãªãã¡ããã·ãã¢ãã-C1-3-ã¢ã«ãã«ãC1-3-ã¢ã«ãã«ã¢ãã-C1-3-ã¢ã«ãã«åã³ãž-(C1-3-ã¢ã«ãã«)-ã¢ãã-C1-3-ã¢ã«ãã«ããéžã°ããïŒåãïŒååã¯ïŒåã®çœ®æåºãå«ãã§ãããããã€ïŒåã¯ãããã«ããäžçœ®æãããŠããŠãããããã€
ååšããã«ã«ããã·åºã®ïŒšåååã¯ïŒ®ååã«çµåãããååã倫ã ã®å Žåã«çäœå ã§éè£ãåŸãåºã«ãã眮æãããŠããŠãããã - åºR1ãR2ãäºã«ç¬ç«ã«ïŒšãC1-6-ã¢ã«ãã«ãC3-5-ã¢ã«ã±ãã«ãC3-5-ã¢ã«ããã«ãC3-7-ã·ã¯ãã¢ã«ãã«ãããããã·-C3-7-ã·ã¯ãã¢ã«ãã«ãC3-7-ã·ã¯ãã¢ã«ãã«-C1-3-ã¢ã«ãã«ãïŒããããã·-C3-7-ã·ã¯ãã¢ã«ãã«ïŒ-C1-3-ã¢ã«ãã«ãããããã·-C2-4-ã¢ã«ãã«ãÏ-NC-C2-3-ã¢ã«ãã«ãC1-4-ã¢ã«ã³ãã·-C2-4-ã¢ã«ãã«ãããããã·-C1-4-ã¢ã«ã³ãã·-C2-4-ã¢ã«ãã«ãC1-4-ã¢ã«ã³ãã·-ã«ã«ããã«-C1-4-ã¢ã«ãã«ãã«ã«ããã·ã«-C1-4-ã¢ã«ãã«ãã¢ãã-C2-4-ã¢ã«ãã«ãC1-4-ã¢ã«ãã«-ã¢ãã-C2-4-ã¢ã«ãã«ããž-(C1-4-ã¢ã«ãã«)-ã¢ãã-C2-4-ã¢ã«ãã«ãã·ã¯ã-C3-6-ã¢ã«ãã¬ã³ã€ãã-C2-4-ã¢ã«ãã«ããããªãžã³-3-ã€ã«ãN-(C1-4-ã¢ã«ãã«)-ãããªãžã³-3-ã€ã«ããããªãžãã«-C1-3-ã¢ã«ãã«ãN-(C1-4-ã¢ã«ãã«)-ãããªãžãã«-C1-3-ã¢ã«ãã«ããããªãžã³-3-ã€ã«ããããªãžã³-4-ã€ã«ãN-(C1-4-ã¢ã«ãã«)-ãããªãžã³-3-ã€ã«ãN-(C1-4-ã¢ã«ãã«)-ãããªãžã³-4-ã€ã«ããããªãžãã«-C1-3-ã¢ã«ãã«ãN-(C1-4-ã¢ã«ãã«)-ãããªãžãã«-C1-3-ã¢ã«ãã«ãããã©ããããã©ã³-3-ã€ã«ãããã©ããããã©ã³-4-ã€ã«ãããã©ããããã©ã³-2-ã€ã«ã¡ãã«ãããã©ããããã©ã³-3-ã€ã«ã¡ãã«ããã§ãã«ããã§ãã«-C1-3-ã¢ã«ãã«ãããªãžã«åã¯ããªãžã«-C1-3-ã¢ã«ãã«ãå«ã矀ããéžã°ããäžèšåºäžã§ãïŒå以äžã®ïŒ£ååãäºãã«ç¬ç«ã«ïŒŠãC1-3-ã¢ã«ãã«åã¯ããããã·-C1-3-ã¢ã«ãã«ã«ããäžçœ®æåã¯å€çœ®æãããŠããŠãããããã€ïŒåã¯ïŒåãããã¯ïŒåã®ççŽ ååãäºã«ç¬ç«ã«ClãBrãOHãCF3ãããã¯CNã«ããäžçœ®æãããŠããŠãããããã€ãã§ãã«åºåã¯ããªãžã«åºãåããããã¯ç°ãªãåºR20ã«ããäžçœ®æåã¯å€çœ®æãããŠããŠããããåã¯ãã§ãã«åºã®å Žåã«ã¯ãŸãæŽã«ãããã«ããäžçœ®æãããŠããŠãããããã€åºR20ãè«æ±é ïŒã«ç€ºãããæå³ãæããããšãç¹åŸŽãšãããè«æ±é ïŒèšèŒã®ã¢ã«ãã³ååç©ã
- R1åã³R2ã¯ããããçµåãããŠããååãšäžç·ã«ãªã£ãŠè€çŽ ç°åºïŒããã¯æå³ãããªãžã³ããããªãžã³ãããã©ãžã³ïŒãã®éé¢ã€ãã³å®èœåºã¯R13ã«ãã眮æãããŠããïŒãåã³ã¢ã«ããªã³ããéžã°ããïŒã圢æãã
ïŒå以äžã®ïŒšååãåãåã¯ç°ãªãåºR14ã«ãã眮æãããŠããŠãããããã€ïŒåã¯
ãã®ç¹å®ãããè€çŽ ç°åºã¯ã¢ã«ãã¬ã³ããªããžãšåºCyã®éã®çµåã
âåçµååã¯äºéçµåãä»ããŠã
âã¹ããç°åŒç°ç³»ã圢æããå ±éã®ïŒ£ååãä»ããŠã
âçž®åäºç°åŒç°ç³»ã圢æããïŒåã®å ±éã®é£æ¥ïŒ£åååã³ïŒåã¯ïŒ®ååãä»ããŠãåã¯
âããªããžãããç°ç³»ã圢æããïŒå以äžã®ïŒ£åååã³ïŒåã¯ïŒ®ååãä»ããŠ
ã€ãããããããªæ§åŒã§ïŒååã¯ïŒåã®åãåã¯ç°ãªãççŽ ç°åºåã¯è€çŽ ç°åºCyã«ãã眮æãããŠããŠãããããã€
åºR13ãR14åã³åºCyãè«æ±é ïŒã«å®çŸ©ããããšããã§ããããšãç¹åŸŽãšãããè«æ±é ïŒèšèŒã®ã¢ã«ãã³ååç©ã - ãåçµååã¯ãšãã¬ã³ãè¡šãããã€ïŒ·ãåçµåãè¡šãããšãç¹åŸŽãšãããè«æ±é ïŒããïŒã®ããããïŒé ã«èšèŒã®ã¢ã«ãã³ååç©ã
- åºïŒ¹ãéšååŒ
åºïŒãåã³ïŒ¬ãCHåºãè¡šããåºïŒããã®äžã€ããŸãååãè¡šããŠããããã〠éšååŒY1ãY2ãY6äžã§ãïŒå以äžã®CHåºãäºãã«ç¬ç«ã«R20ã«ãã眮æãããŠããŠãããããã€
éšååŒY6äžã§ãNHåºãC1-4-ã¢ã«ãã«ã«ãã眮æãããŠããŠãããã
R20ãè«æ±é ïŒã«å®çŸ©ããããšããã§ããïŒ
ã®äžããéžã°ããããšãç¹åŸŽãšãããè«æ±é ïŒããïŒã®ããããïŒé ã«èšèŒã®ã¢ã«ãã³ååç©ã - åºïŒ¡ãïŒäŸ¡ã®ç°åŒåºãã§ãã«ãããªãžãã«ãããªããžãã«ããã©ãžãã«åã¯ããªããžãã«ã®äžããéžã°ããããããïŒå以äžã®ïŒ£ååã®äœçœ®ã§åãåã¯ç°ãªãåºR20ã«ããäžçœ®æåã¯å€çœ®æãããŠããŠããããåã¯ãã§ãã«ç°ã®å Žåã«ã¯ãŸãæŽã«ãããã«ããäžçœ®æãããŠããŠãããããã€
R20ãè«æ±é ïŒã«ç€ºãããæå³ãæããããšãç¹åŸŽãšãããè«æ±é ïŒããïŒã®ããããïŒé ã«èšèŒã®ã¢ã«ãã³ååç©ã - åºïŒ¢ããã§ãã«ãã·ã¯ãããã»ãã«ãããªãžã«ãããšãã«åã³ãã©ãã«ã®äžããéžã°ãããã€
äžèšç°åŒåºãïŒå以äžã®ïŒ£ååã®äœçœ®ã§åãåã¯ç°ãªãåºR20ã«ããäžçœ®æåã¯å€çœ®æãããŠããŠããããåã¯ãã§ãã«åºã®å Žåã«ã¯ãŸãæŽã«ãããã«ããäžçœ®æãããŠããŠãããããã€
R20ãè«æ±é ïŒã«ç€ºãããæå³ãæããããšãç¹åŸŽãšãããè«æ±é ïŒããïŒã®ããããïŒé ã«èšèŒã®ã¢ã«ãã³ååç©ã - è«æ±é ïŒããïŒã®ããããïŒé ã«èšèŒã®ã¢ã«ãã³ååç©ã®ççåŠäžèš±ãããå¡©ã
- å¿ èŠã«ããäžçš®ä»¥äžã®äžæŽ»æ§æ äœåã³ïŒåã¯åžéå€ãšäžç·ã«è«æ±é ïŒããïŒã®ããããïŒé ã«èšèŒã®å°ãªããšãäžçš®ã®ã¢ã«ãã³ååç©åã³ïŒåã¯è«æ±é ïŒèšèŒã®å¡©ãå«ãããšãç¹åŸŽãšããå»è¬çµæç©ã
- è«æ±é ïŒããïŒã®ããããïŒé ã«èšèŒã®å°ãªããšãäžçš®ã®ã¢ã«ãã³ååç©åã³ïŒåã¯è«æ±é ïŒèšèŒã®å¡©ãå«æãããåºä¹³é¡ã®é£äºæåã«åœ±é¿ããããã®å»è¬çµæç©ã
- è«æ±é ïŒããïŒã®ããããïŒé ã«èšèŒã®å°ãªããšãäžçš®ã®ã¢ã«ãã³ååç©åã³ïŒåã¯è«æ±é ïŒèšèŒã®å¡©ãå«æãããåºä¹³é¡ã®äœéãæžå°ãããã€ïŒåã¯äœéã®å¢å ãé²æ¢ããããã®å»è¬çµæç©ã
- MCHå容äœæ®æ掻æ§ãæããå»è¬çµæç©ã調補ããããã®è«æ±é ïŒããïŒã®ããããïŒé ã«èšèŒã®å°ãªããšãäžçš®ã®ã¢ã«ãã³ååç©åã³ïŒåã¯è«æ±é ïŒèšèŒã®å¡©ã®äœ¿çšã
- MCHã«ããåŒãèµ·ããããåã¯ãã以å€ã«MCHãšåå äžé¢é£ããŠããçååã³ïŒåã¯çŸæ£ã®äºé²åã³ïŒåã¯æ²»çã«é©ããŠããå»è¬çµæç©ã調補ããããã®è«æ±é ïŒããïŒã®ããããïŒé ã«èšèŒã®å°ãªããšãäžçš®ã®ã¢ã«ãã³ååç©åã³ïŒåã¯è«æ±é ïŒèšèŒã®å¡©ã®äœ¿çšã
- 代è¬é害åã³ïŒåã¯é£äºé害ãç¹ã«è¥æºãå€é£çãç¥çµæ§å€é£çãæªæ¶²è³ªãæé£çãç¥çµæ§é£æ¬²äžæ¯äžŠã³ã«éé£çã®äºé²åã³ïŒåã¯æ²»çã«é©ããŠããå»è¬çµæç©ã調補ããããã®è«æ±é ïŒããïŒã®ããããïŒé ã«èšèŒã®å°ãªããšãäžçš®ã®ã¢ã«ãã³ååç©åã³ïŒåã¯è«æ±é ïŒèšèŒã®å¡©ã®äœ¿çšã
- å¿ èŠã«ããäžçš®ä»¥äžã®äžæŽ»æ§æ äœåã³ïŒåã¯åžéå€ãšäžç·ã«ã
è«æ±é ïŒããïŒã®ããããïŒé ã«èšèŒã®ã¢ã«ãã³ååç©åã³ïŒåã¯è«æ±é ïŒèšèŒã®å¡©ããéžã°ãã第äžæŽ»æ§ç©è³ªãåã³
ç³å°¿ç ã®æ²»çã®ããã®æŽ»æ§ç©è³ªãç³å°¿ç ã®å䜵çã®æ²»çã®ããã®æŽ»æ§ç©è³ªãè¥æºã®æ²»çã®ããã®æŽ»æ§ç©è³ªã奜ãŸããã¯MCHã¢ã³ã¿ãŽãã¹ã以å€ãé«è¡å§ã®æ²»çã®ããã®æŽ»æ§ç©è³ªãåè硬åãå«ããé«èè¡çã®æ²»çã®ããã®æŽ»æ§ç©è³ªãé¢ç¯çã®æ²»çã®ããã®æŽ»æ§ç©è³ªãäžå®ç¶æ ã®æ²»çã®ããã®æŽ»æ§ç©è³ªåã³é¬±ç ã®æ²»çã®ããã®æŽ»æ§ç©è³ªãããªã矀ããéžã°ãã第äºæŽ»æ§ç©è³ª
ãå«ãããšãç¹åŸŽãšããå»è¬çµæç©ã - åŒA.5
R1R2N-Y-C=C-W-A-B (A.5)
ïŒåŒA.1ãA.2ãA.3ãA.4åã³A.5äžãR1ãR2ãããåã³ïŒ¢ã¯è«æ±é ïŒããïŒã«ç€ºãããæå³ã®äžã€ãæããïŒ
ã®ã¢ã«ãã³ååç©ã®èª¿è£œæ¹æ³ã§ãã£ãŠã
åŒA.1
HO-Y-Hal (A.1)
ïŒåŒäžãHalã¯å¡©çŽ ãèçŽ åã¯ãšãŠçŽ ã奜ãŸããã¯èçŽ åã¯ãšãŠçŽ ãè¡šãïŒ
ã®ããã²ã³ååç©ã奜é©ãªæº¶åªäžã§å¥œé©ãªãã©ãžãŠã 觊åªã奜é©ãªå¡©åºåã³ãšãŠåé (I)ã®ååšäžã§åŒA.2
H-C=C-W-A-B (A.2)
ã®ã¢ã«ãã³ååç©ãšåå¿ããããããŠ
åŸãããåŒA.3
HO-Y-C=C-W-A-B (A.3)
ã®ååç©ã奜é©ãªããã²ã³åå€ãšåå¿ãããŠãã©ã€ãèªå°äœA.4
Hal'-Y-C=C-W-A-B (A.4)
ïŒåŒäžãHal'ã¯ClãBråã¯ïŒ©ãè¡šãïŒ
ãçæãã
ãããæŽã«åŒH-NR1R2ã®ã¢ãã³ãšåå¿ãããŠæçµçæç©A.5ãçæããããšãç¹åŸŽãšãããäžèšã¢ã«ãã³ååç©ã®èª¿è£œæ¹æ³ã - åŒB.5
R1R2N-Y-Z-C=C-A-B (B.5)
ïŒåŒB.1ãB.2ãB.3ãB.4åã³B.5äžãR1ãR2ãããåã³ïŒ¢ã¯è«æ±é ïŒããïŒã«ç€ºãããæå³ã®äžã€ãæããïŒ
ã®ã¢ã«ãã³ååç©ã®èª¿è£œæ¹æ³ã§ãã£ãŠã
åŒB.1
Hal-A-B (B.1)
ïŒåŒäžãHalã¯å¡©çŽ ãèçŽ åã¯ãšãŠçŽ ã奜ãŸããã¯èçŽ åã¯ãšãŠçŽ ãè¡šãïŒ
ã®ããã²ã³ååç©ã奜é©ãªæº¶åªäžã§å¥œé©ãªãã©ãžãŠã 觊åªã奜é©ãªå¡©åºåã³ãšãŠåé (I)ã®ååšäžã§åŒB.2
HO-Y-Z-C=C-H (B.2)
ã®ã¢ã«ãã³ååç©ãšåå¿ããããããŠ
åŒB.3
HO-Y-Z-C=C-A-B (B.3)
ã®åŸãããååç©ã奜é©ãªããã²ã³åå€ãšåå¿ãããŠãã©ã€ãèªå°äœB.4
Hal'-Y-Z-C=C-A-B (B.4)
ïŒåŒäžãHal'ã¯ClãBråã¯ïŒ©ãè¡šãïŒ
ãçæãã
ãããæŽã«åŒH-NR1R2ã®ã¢ãã³ãšåå¿ãããŠæçµçæç©B.5ãçæããããšãç¹åŸŽãšãããäžèšã¢ã«ãã³ååç©ã®èª¿è£œæ¹æ³ã - åŒC.3
R1R2N-Y-C=C-W-A-B (C.3)
ïŒåŒC.1ãC.2åã³C.3äžãR1ãR2ãããåã³ïŒ¢ã¯è«æ±é ïŒããïŒã«ç€ºãããæå³ã®äžã€ãæããïŒ
ã®ã¢ã«ãã³ååç©ã®èª¿è£œæ¹æ³ã§ãã£ãŠã
åŒC.1
R1R2N-Y-Hal (C.1)
ïŒåŒäžãHalã¯å¡©çŽ ãèçŽ åã¯ãšãŠçŽ ã奜ãŸããã¯èçŽ åã¯ãšãŠçŽ ãè¡šãïŒ
ã®ããã²ã³ååç©ã奜é©ãªæº¶åªäžã§å¥œé©ãªãã©ãžãŠã 觊åªã奜é©ãªå¡©åºåã³ãšãŠåé (I)ã®ååšäžã§åŒC.2
H-C=C-W-A-B (C.2)
ã®ã¢ã«ãã³ååç©ãšæŽã«ãããŠæçµçæç©C.3ãçæããããšãç¹åŸŽãšãããäžèšã¢ã«ãã³ååç©ã®èª¿è£œæ¹æ³ã - åŒD.3
R1R2N-Y-Z-C=C-A-B (D.3)
ïŒåŒD.1ãD.2åã³D.3äžãR1ãR2ãããåã³ïŒ¢ã¯è«æ±é ïŒããïŒã«ç€ºãããæå³ã®äžã€ãæããïŒ
ã®ã¢ã«ãã³ååç©ã®èª¿è£œæ¹æ³ã§ãã£ãŠã
åŒD.2
Hal-A-B (D.2)
ïŒåŒäžãHalã¯å¡©çŽ ãèçŽ åã¯ãšãŠçŽ ã奜ãŸããã¯èçŽ åã¯ãšãŠçŽ ãè¡šãïŒ
ã®ããã²ã³ååç©ã奜é©ãªæº¶åªäžã§å¥œé©ãªãã©ãžãŠã 觊åªã奜é©ãªå¡©åºåã³ãšãŠåé (I)ã®ååšäžã§åŒD.1
R1R2N-Y-Z-C=C-H (D.1)
ã®ã¢ã«ãã³ååç©ãšåå¿ãããŠæçµçæç©D.3ãçæããããšãç¹åŸŽãšãããäžèšã¢ã«ãã³ååç©ã®èª¿è£œæ¹æ³ã
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004017932A DE102004017932A1 (de) | 2004-04-14 | 2004-04-14 | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
PCT/EP2005/003684 WO2005103029A1 (de) | 2004-04-14 | 2005-04-08 | Neue alkin-verbindungen mit mch-antagonistischer wirkung und diese verbindungen enthaltende arzneimittel |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007532594A JP2007532594A (ja) | 2007-11-15 |
JP2007532594A5 true JP2007532594A5 (ja) | 2008-05-29 |
Family
ID=34966977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007507707A Pending JP2007532594A (ja) | 2004-04-14 | 2005-04-08 | ïŒïœïœæ®æäœçšãæããæ°èŠã¢ã«ãã³ååç©åã³åèšååç©ãå«ãå»è¬ |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1737839A1 (ja) |
JP (1) | JP2007532594A (ja) |
CA (1) | CA2559237A1 (ja) |
DE (1) | DE102004017932A1 (ja) |
WO (1) | WO2005103029A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7452911B2 (en) | 2002-10-31 | 2008-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
DE10323345A1 (de) | 2003-05-23 | 2004-12-16 | Zentaris Gmbh | Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren |
US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
MX2009000334A (es) | 2006-08-25 | 2009-01-28 | Boehringer Ingelheim Int | Nuevos derivados de piridona con actividad antagonista de mch y medicamentos que comprenden estos compuestos. |
CL2007003580A1 (es) | 2006-12-11 | 2009-03-27 | Boehringer Ingelheim Int | Compuestos derivados de piridazina, antagonistas de mch; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos metabolicos y/o trastornos alimentarios como obesidad, bulimia, anorexia, hiperfagia, diabetes. |
JP5514716B2 (ja) * | 2007-05-11 | 2014-06-04 | ã³ãªã¢ã»ãªãµãŒãã»ã€ã³ã¹ãã£ãã¥ãŒãã»ãªãã»ã±ãã«ã«ã»ãã¯ãããžãŒ | ã¢ãªãŒã«ãããªãžã³çœ®æåºãæããã€ãããŸãŒã«èªå°äœããã®è£œé æ¹æ³åã³ãããå«ãå»è¬çµæç© |
JP5535931B2 (ja) * | 2008-10-27 | 2014-07-02 | æŠç°è¬åå·¥æ¥æ ªåŒäŒç€Ÿ | äºç°æ§ååç© |
EP3485889B1 (en) * | 2011-12-16 | 2023-09-06 | Poseida Therapeutics, Inc. | Trpc4 modulators for use in the treatment or prevention of pain |
US11332459B2 (en) | 2017-10-19 | 2022-05-17 | Teijin Pharma Limited | Benzimidazole derivatives and their uses |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7315700A (en) * | 1999-09-20 | 2001-04-24 | Takeda Chemical Industries Ltd. | Melanin concentrating hormone antagonist |
JP2002003370A (ja) * | 1999-09-20 | 2002-01-09 | Takeda Chem Ind Ltd | ã¡ã©ãã³åéãã«ã¢ã³æ®æå€ |
JP2002241274A (ja) * | 2000-04-28 | 2002-08-28 | Takeda Chem Ind Ltd | ã¡ã©ãã³åéãã«ã¢ã³æ®æå€ |
DE10139416A1 (de) * | 2001-08-17 | 2003-03-06 | Aventis Pharma Gmbh | Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
AU2002352878B2 (en) * | 2001-11-27 | 2007-11-22 | Merck Sharp & Dohme Corp. | 2-Aminoquinoline compounds |
JP2005529923A (ja) * | 2002-05-13 | 2005-10-06 | ã€ãŒã©ã€ã»ãªãªãŒã»ã¢ã³ãã»ã«ã³ãã㌠| è¥æºããã³ç³å°¿ç ã®æ²»çã«ãããã¡ã©ãã³åéãã«ã¢ã³ã¢ã³ã¿ãŽãã¹ããšããŠäœ¿çšããããã®å€ç°åŒååç© |
WO2004031177A1 (ja) * | 2002-09-30 | 2004-04-15 | Banyu Pharmaceutical Co., Ltd. | ïŒâã¢ãããã³ãºã€ãããŸãŒã«èªå°äœ |
DE10250708A1 (de) * | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
JP4630555B2 (ja) * | 2003-02-12 | 2011-02-09 | æŠç°è¬åå·¥æ¥æ ªåŒäŒç€Ÿ | ã¢ãã³èªå°äœ |
-
2004
- 2004-04-14 DE DE102004017932A patent/DE102004017932A1/de not_active Withdrawn
-
2005
- 2005-04-08 WO PCT/EP2005/003684 patent/WO2005103029A1/de not_active Application Discontinuation
- 2005-04-08 JP JP2007507707A patent/JP2007532594A/ja active Pending
- 2005-04-08 EP EP05739806A patent/EP1737839A1/de not_active Withdrawn
- 2005-04-08 CA CA002559237A patent/CA2559237A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007532594A5 (ja) | ||
JP2007532596A5 (ja) | ||
CA2012432C (en) | N-(3-hydroxy-4piperidinyl)(dihydrobenzofuran, dihydro-2h-benzopyran or dihydrobenzodioxin) carboxamide derivatives | |
JP3014367B2 (ja) | ïœïœâïŒå容äœã¢ã³ã¿ãŽãã¹ã | |
JP3073238B2 (ja) | ïŒâïŒïŒïŒïŒâãžçœ®æãããªãžãã«ïŒâïŒâ眮æããã©ãžã³èªå°äœ | |
JP2010512366A5 (ja) | ||
RU2008120619A (ru) | (геÑеÑП)аÑОлÑ, ПблаЎаÑÑОе аМÑагПМОÑÑОÑеÑкПй акÑОвМПÑÑÑÑ Ð¿ÐŸ ПÑМПÑÐµÐœÐžÑ Ðº ЌелаМОМкПМÑеМÑÑОÑÑÑÑÐµÐŒÑ Ð³ÐŸÑÐŒÐŸÐœÑ | |
CZ289250B6 (cs) | 2,4-DiaminopyrimidinovÃœ derivát, způsob jeho pÅÃpravy a pouÄŸità a farmaceutickÃœ prostÅedek na jeho bázi | |
JP2005516006A5 (ja) | ||
WO2009022730A1 (ja) | ïŒïœïŒå容äœæ®æå€ | |
US6319920B1 (en) | 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives | |
CA2420177C (en) | Quinazoline derivatives as alpha-1 adrenergic antagonists | |
CA2559237A1 (en) | Novel alkyne compounds having an mch-antagonistic effect and medicaments containing said compounds | |
Fiorino et al. | New 5-HT1A, 5HT2A and 5HT2C receptor ligands containing a picolinic nucleus: Synthesis, in vitro and in vivo pharmacological evaluation | |
JP2007528884A5 (ja) | ||
JP2007527424A5 (ja) | ||
JP2007532593A5 (ja) | ||
JPH11130773A (ja) | æ°èŠãªã€ã³ããŒã«åã³ã€ã³ããŸãŒã«ååç©ããããã®è£œé æ¹æ³ã䞊ã³ã«ããããå«æããå»è¬çµæç© | |
JP4322675B2 (ja) | ã ã¹ã«ãªã³å容äœã¢ã³ã¿ãŽãã¹ããšããŠã®ã¢ããããã©ãªã³èªå°äœ | |
JP2007532599A5 (ja) | ||
KR20230035349A (ko) | ìë©Ž 묎íží¡ì ì¹ë£ë¥Œ ìí ìí2-ìëë ë 늰ìì©ì²Ž íìì í c (ìí-2c) êžžíì ì task1/3 ì±ë ì°šëšì ì ì¡°í©ë¬Œ | |
JP2006503056A (ja) | ãã¹ã¿ãã³ïœïŒå容äœã¢ã³ã¿ãŽãã¹ãããã®è£œé ããã³æ²»ççšäœ¿çš | |
JP2007520466A5 (ja) | ||
JP4660198B2 (ja) | 眮æïŒâãããªãžã³âïŒâã€ã«âïŒâãããªãžã³âïŒâã€ã«âããã©ãžã³èªå°äœããã³ãããã®ãã¥ãŒãããã³æ®æè¬ãšããŠã®äœ¿çš | |
US20050267115A1 (en) | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |